Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Change in Accured Expenses: 2013-2025

Historic Change in Accured Expenses for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $25.3 million.

  • Amphastar Pharmaceuticals' Change in Accured Expenses rose 2.80% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.2 million, marking a year-over-year decrease of 30.77%. This contributed to the annual value of $63.6 million for FY2024, which is 380.19% up from last year.
  • Amphastar Pharmaceuticals' Change in Accured Expenses amounted to $25.3 million in Q3 2025, which was up 621.57% from -$4.9 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Change in Accured Expenses ranged from a high of $25.3 million in Q3 2025 and a low of -$14.7 million during Q3 2021.
  • Moreover, its 3-year median value for Change in Accured Expenses was $8.0 million (2023), whereas its average is $10.4 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first plummeted by 1,162.27% in 2022, then skyrocketed by 2,803.38% in 2023.
  • Amphastar Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at -$1.1 million in 2021, then slumped by 1,162.27% to -$13.6 million in 2022, then soared by 75.06% to -$3.4 million in 2023, then skyrocketed by 162.34% to $2.1 million in 2024, then rose by 2.80% to $25.3 million in 2025.
  • Its Change in Accured Expenses stands at $25.3 million for Q3 2025, versus -$4.9 million for Q2 2025 and $17.6 million for Q1 2025.